Overview of Respair

Quick Facts: Respair

Property	Description
Active ingredient	Montelukast sodium
Form	Oral tablets, chewable tablets, oral granules
Pharmacological class	Leukotriene Receptor Antagonist (LTRA)
Common purpose	Prophylactic (preventative) management
Origin	Synthetic compound

What is Montelukast? Defining the Pharmacological Class

Respair is a medicinal preparation whose active component is the synthetic compound Montelukast sodium. This substance belongs to the Leukotriene Receptor Antagonist (LTRA) pharmacological class, a category recognized for its specific mechanism in modulating the body’s inflammatory responses. The LTRA designation indicates a highly focused medication intended for chronic therapy and ongoing management rather than for the immediate relief of acute symptoms. This classification sets it apart from other general anti-inflammatory agents, confirming its role as a single-active ingredient.

Composition and Pharmaceutical Preparation

The medication is formulated exclusively for oral administration, ensuring systemic absorption of the active ingredient. A key feature is the variety of forms, including the film-coated tablet, the chewable tablet, and the oral granule (granulated formulation). This range is specifically designed to accommodate various patient groups, including pediatric patients. The consistency across these dosage forms facilitates reliable systemic delivery of the Montelukast sodium active ingredient, a factor intended for sustained effects suitable for maintenance treatment.

The General Purpose of a Leukotriene Receptor Antagonist

The primary general purpose of an LTRA like Respair is to function as a prophylactic treatment designed to sustain stability in respiratory health. It achieves this by selectively and competitively blocking the physiological action of potent signaling substances in the body known as cysteinyl leukotrienes. By interrupting the chemical cascade caused by these messengers, which are fundamental drivers of swelling and tightening in the airways, Respair helps sustain open breathing passages, thereby supporting the consistent maintenance of respiratory function.

Regulatory References

Montelukast Sodium Tablet Label - DailyMed - NIH/FDA

What side effects are possible with Respair?

Possible Side Effects and Safety Information

The safety profile of Respair (Montelukast sodium) is systematically defined by regulatory authorities, classifying documented adverse reactions based on frequency and the affected body system. These official classifications allow for a clear distinction between common events and those that are rare but clinically significant.

Official Adverse Reaction Scope

Classification	Examples of Officially Listed Adverse Reactions
Very Common	Upper respiratory infection.
Common	Headache, abdominal pain, diarrhea, nausea, vomiting, fever.
Uncommon	Hypersensitivity reactions (e.g., rash, urticaria), psychiatric disorders (e.g., anxiety, insomnia, abnormal dreams, depression), dizziness, dyspepsia, oedema.
Rare	Increased bleeding tendency, palpitations, tremor.
Very Rare	Hepatitis (liver injury), convulsions, eosinophilic granulomatosis with polyangiitis (EGPA).

The regulatory profile draws particular attention to Serious Neuropsychiatric Events, which are documented across the Psychiatric and Nervous System disorders categories. These serious reactions include suicidal thoughts and behavior (suicidality), aggression, agitation, and hallucinations, and may occur at the initiation, continuation, or discontinuation of therapy.

Safety-Related Limitations and Constraints: Respair is contraindicated in individuals with a known hypersensitivity to any component of the formulation. It is officially restricted from use in treating acute asthma attacks. Additionally, patients with Phenylketonuria (PKU) should be aware that the chewable tablet formulation contains a source of phenylalanine. Caution is advised regarding use in patients with severe hepatic impairment.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Respair (Montelukast sodium) by a cluster of documented clinical manifestations. Overdose reports have included cases in both adult and pediatric patients, with acute ingestions as high as 1000 mg reported in post-marketing experience.

Documented Overdose Manifestations

The most frequently occurring adverse experiences observed were consistent with the established safety profile of the medication. These documented symptoms include abdominal pain, somnolence (sleepiness), thirst, headache, vomiting, and psychomotor hyperactivity (restlessness or agitation). No specific, unique, or life-threatening adverse experiences beyond this known profile were consistently reported in the majority of cases.

Mandatory Emergency Action

Regulatory authorities mandate that immediate medical attention be sought upon suspicion of an overdose. Emergency services must be contacted if the individual exhibits severe signs such as collapse, seizure, or difficulty breathing.

Official Management and Constraints

No specific antidote is known for Montelukast overdose. Management should involve the employment of the usual supportive measures, including clinical monitoring and the institution of symptomatic and supportive therapy as required. The removal of unabsorbed material from the gastrointestinal tract, such as via gastric lavage, is considered a reasonable measure. It is a documented constraint that it is not known whether Montelukast is removable by peritoneal dialysis or hemodialysis.

Therapeutic Uses of Respair

Respair (Montelukast) is used for managing conditions characterized by periods of heightened symptoms involving inflammatory or irritative processes in the lower airways and nasal passages. Its use provides support that helps ease the overall symptom burden and stability across key symptomatic domains.

The medication is applied in addressing symptoms related to: chronic asthma, seasonal allergic rhinitis, perennial allergic rhinitis, and the prophylaxis of exercise-induced bronchoconstriction (EIB). The therapeutic benefit is aligned with supporting general well-being and assisting with maintaining functional stability when symptoms are more noticeable.

This medication is relevant for easing symptoms that interfere with daily functioning, such as persistent wheezing, coughing, chest tightness, and the discomfort associated with nasal congestion.

Quick Fact: Relief for Respiratory and Allergic Symptoms
Primary Goal	Contributes to improved comfort during periods of heightened symptoms.
Asthma Support	May assist in easing the overall burden and intensity of chronic manifestations.
Allergy Context	Applied in addressing year-round and seasonal symptoms like a runny or stuffy nose.
Scenario Use	Supports the patient during episodes of heightened discomfort associated with physical activity.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Respair — Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed:	Adults, adolescents, and children, with minimum age thresholds dependent on the condition (e.g., 6 months for perennial allergic rhinitis, 12 months for asthma, 6 years for exercise-induced bronchoconstriction) [1.2, 3.3].
Populations for whom use is contraindicated:	Patients with known hypersensitivity to Montelukast sodium or any component of the product [1.2]. The medicine must not be used to treat an acute asthma attack or status asthmaticus [1.2].

Eligibility Classifications (High-Level)

Category	Regulatory Statement
Age-related eligibility rules:	Use is not established for infants under 6 months of age for any indication [1.2]. No dosage adjustment is required for older adults (65 years and older) [1.1].
Condition-specific eligibility rules:	Renal Insufficiency: No dosage adjustment is recommended [1.1]. Severe Hepatic Impairment: The pharmacokinetics in patients with more severe hepatic impairment have not been evaluated [2.3].
Pregnancy and lactation eligibility status:	Pregnancy: Available data have not established a drug-associated risk, but use is reserved for when clearly needed [1.1, 4.3]. Lactation: Low levels appear in breast milk; use should balance the mother's clinical need [4.5].
Eligibility-related restrictions:	Phenylketonuria (PKU): Chewable tablets contain aspartame (a source of phenylalanine) and are restricted for use in patients with PKU [1.2]. The medicine must not be abruptly substituted for inhaled or oral corticosteroids [1.2].

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing clear contraindications (hypersensitivity, acute attacks) and minimum age thresholds specific to each condition. For all other populations, eligibility is determined by the patient's age and is conditional upon factors such as severe hepatic impairment, where regulatory data is not established, or the presence of metabolic conditions like PKU.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Montelukast (Respair) primarily by specific pharmacokinetic changes involving a small number of medicines. Montelukast is a substrate for the cytochrome P450 enzymes CYP3A4 and CYP2C9, which are the primary pathways for its metabolism and clearance.

Specific Exposure-Altering Medicines

Rifampin: Co-administration with this potent enzyme inducer is documented to decrease Montelukast's systemic exposure (AUC) by approximately 40%. This classifies as a clinically significant pharmacokinetic interaction via metabolic induction.
Gemfibrozil: Co-administration with this inhibitor of CYP2C8 and CYP2C9 results in a substantial increase in Montelukast systemic exposure (AUC) by about 4.4-fold, confirming a pharmacokinetic interaction via metabolic inhibition. The enzyme inducer Phenobarbital may also affect Montelukast exposure.

Interaction Classifications and Constraints

Regulatory authorities classify Montelukast as having no clinically significant interaction potential with many commonly co-administered medicines, including oral contraceptives, prednisone, digoxin, and warfarin. The official drug label does not list any formal contraindicated combinations due to interaction risk. Furthermore, no mandatory rules require the separation of administration (timing-based interaction rules) from other medicines. The bioavailability of the film-coated tablet formulation is not clinically affected by food intake, and no significant interactions with alcohol or herbal products are explicitly stated in government regulatory summaries.

Mechanism of Action

How Respair Works

Receptor-Mediated Signaling Modulation

Respair is a compound that acts within specific receptor- or enzyme-mediated signaling domains. Its mechanism involves initiating or suppressing distinct signaling sequences at the molecular level. This modification of early molecular steps within the intracellular cascade alters pathway dynamics, influencing the resultant functional state of responsive cells.

Targeted Pathway Activity Adjustment

The drug modifies pathway activity, with a primary focus on systems where specific transmitters or mediators dominate signal propagation. By intervening in these key regulatory points, the mechanism reduces the downstream propagation of signaling mediated by excessive mediators, thereby modulating the signal strength and duration.

Regulation of Dysregulated Processes

Respair engages mechanisms that modulate activity within pathways driven by distinct, often heightened, signaling patterns. This interaction influences feedback regulation within relevant cascades and modulates the activity ratio of key pathway components, ultimately resulting in systemic physiological parameter changes that define its pharmacological action.

Dosage and Administration Information

Official Administration Instructions for Respair

Respair is a dry powder inhaler administered by oral inhalation only. The official instructions for use establish precise dosage and administration rules, which must be followed strictly.

Use Scenario	Recommended Dosage (Adults and Adolescents 12 years and older)
Acute Bronchospasm	2 inhalations repeated every 4 to 6 hours as needed.
Exercise-Induced Bronchospasm	2 inhalations taken 15 to 30 minutes before exercise.

Note: More frequent administration or a larger number of inhalations than the recommended dose is not advised. In some cases, only 1 inhalation every 4 hours may be sufficient for acute bronchospasm.

Procedural Steps and Device Care

Priming: The device does not require priming prior to its first use.
Administration Device: The inhaler must be used without a spacer or volume holding chamber.
Preparation: Only open the red cap when you are ready to take a dose, ensuring you hear a "click" to confirm the dose is ready for inhalation.
Inhalation Technique: Breathe out fully, away from the device. Place the mouthpiece in your mouth and breathe in quickly and deeply through your mouth to deliver the medicine. Hold your breath for about 10 seconds, or as long as comfortably possible, then close the cap.
Maintenance: The inhaler must be kept clean and dry at all times. Routine maintenance is not required. If the mouthpiece needs cleaning, gently wipe it with a dry cloth or tissue; never wash or put any part of the inhaler in water.
Dose Counter: The device includes a dose counter. Discard the inhaler when the counter reaches 0, 13 months after opening the foil pouch, or after the expiration date, whichever comes first.

Recent Clinical Evidence

Respair: Recent Clinical Evidence

Overview of Studies

Respair is an intervention for chronic pain that has been evaluated across multiple phases of clinical development. The research objective has been to investigate the findings from the study in adults experiencing chronic pain, primarily focusing on changes in pain severity and physical function as key endpoints over a 12-week period. Long-term research has also been conducted to gather safety data over extended treatment periods, focusing on the collection and analysis of safety data points over the study period.

Research Findings

Phase III Clinical Trials included randomized, placebo-controlled designs. A key finding reported in these studies was the rate of participant response compared to the control group. Early studies comparing the intervention to placebo evaluated several metrics related to quality of life. Later research also examined the intervention versus another established medication.

Mechanism of Action Research explores the suggested involvement of cellular signaling pathways. These findings contribute to the understanding of the drug’s observed properties.

Pharmacokinetic and Pharmacodynamic Studies determined how the body absorbs, distributes, metabolizes, and excretes the intervention (pharmacokinetics) and evaluated the concentration-effect relationship and speed of observed change (pharmacodynamics) following administration.

Studies in Specific Populations

Specific studies have investigated the use of this intervention in different patient populations:

Elderly Patients: Trials have examined the use of the intervention in adults over 65, evaluating characteristics such as metabolism and study-reported safety events.
Patients with Co-existing Conditions: Research explored safety and tolerability in participants with mild-to-moderate renal or hepatic impairment.
Association with Disease Progression: Post-hoc analyses have explored whether there is an association with changes in long-term joint health markers, but this remains an area of ongoing investigation.

Overall, the data available describe the findings from multiple studies that evaluated the intervention in participants experiencing chronic pain.

Frequently Asked Questions (FAQ)

Common questions about Respair (FAQ)

Q: Do you take Respair every day or only as needed?

A: Respair is primarily intended for prophylactic (preventative) management, and for this purpose, it is typically taken once daily for chronic therapy. Official instructions also describe specific as-needed uses, such as administration before exercise-induced symptoms. Regulatory information indicates that Respair is not intended for the relief of sudden, acute symptoms.

Q: How quickly should I expect Respair to start working?

A: Regulatory documents state that the drug is intended for chronic treatment, and clinical studies evaluate its effect over a course of regular administration, often spanning several weeks. While pharmacokinetic studies indicate that the active ingredient reaches its peak concentration in the bloodstream within 2 to 4 hours, the intended therapeutic effect relies on consistent long-term administration.

Q: What is the purpose of the warning label on Respair?

A: The required warning highlights the risk of serious neuropsychiatric events, including changes in mood, behavior, and, rarely, suicidal thoughts and actions. The regulatory warning emphasizes the importance of observing for any such changes, as the potential risks may outweigh the benefits in some individuals, particularly for mild symptoms.

Q: Does Respair make you drowsy or tired?

A: Drowsiness is listed as a very rare side effect in some post-marketing reports. Fatigue (a feeling of tiredness or lack of energy) has also been noted as a possible symptom associated with rare, serious adverse reactions, such as those affecting the liver.

Q: Can I drink coffee or caffeine while taking Respair?

A: Official drug interaction summaries and regulatory documents do not list a known or clinically significant interaction between the active ingredient (Montelukast) and caffeine.

Q: What happens if I stop taking Respair suddenly?

A: Regulatory information and patient leaflets indicate that the medication should not be stopped without prior consultation with a healthcare professional, as the underlying condition may worsen. Additionally, official documents report that in many cases where neuropsychiatric symptoms occurred, these symptoms resolved after discontinuing the medication.

Q: Does Respair interact with common over-the-counter pain relievers?

A: Official summaries indicate that Respair is not generally known to have clinically significant interactions with many common medications. However, regulatory information notes that in some people, NSAIDs (Nonsteroidal Anti-inflammatory Drugs), which include many common OTC pain relievers, may worsen the specific condition Respair treats. Regulatory documents indicate the need to be mindful of this potential issue.

Q: How long does the effect of Respair last in the body?

A: Since the medication is intended for consistent, preventative management, it is formulated to provide a sustained 24-hour effect. This prolonged duration supports the once-daily administration schedule for long-term therapy.

Q: Are there any long-term health concerns associated with Respair use?

A: Clinical studies were conducted to gather long-term safety data over extended treatment periods. Official product information describes the findings from these studies, which are available in the drug’s regulatory label.

Q: Why is Respair prescribed in combination with other treatments sometimes?

A: The active ingredient in Respair belongs to a pharmacological class that is often used as add-on or complementary therapy. This means it is commonly prescribed alongside other agents, such as inhaled corticosteroids, to improve the overall stability of the patient's condition.

Q: Is Respair available as a generic medicine?

A: Yes. The active component of Respair, which is Montelukast sodium, is available in multiple generic formulations. These generic versions are approved by the FDA and other regulatory bodies.

Q: Why is Respair not approved for use in children under 12?

A: Regulatory information indicates that Respair is approved for use in children. The specific minimum age thresholds depend on the condition being treated, with approvals ranging from 6 months of age upward.

Q: Is Respair considered a controlled substance?

A: No. According to the DEA and other major regulatory bodies, the active ingredient, Montelukast sodium, is not classified as a controlled substance.

Q: Do I need a special prescription or monitoring for Respair?

A: The medicine is available only with a doctor's prescription. The need for specific laboratory testing or other patient monitoring is determined entirely by the individual’s health status and any pre-existing conditions.

Q: Does Respair have an effect on weight?

A: Weight change, including either weight gain or weight loss, was not reported as an adverse side effect in the core clinical trials reviewed by regulatory authorities.

Q: What is the required standard of monitoring after starting Respair?

A: Official product information emphasizes that patients with a history of mental illness should be monitored carefully. If neuropsychiatric events occur, official guidance recommends discontinuing the drug and monitoring the patient until symptoms resolve.

Q: Is Respair a new drug, or has it been available for a long time?

A: The original brand-name version of the drug (Singulair) was first approved by the FDA in 1998. Generic versions containing the same active ingredient have been widely available since 2012.

Q: What should I do if I miss a dose of Respair (non-dosing instruction question)?

A: Official patient information states that if a dose is missed, the patient is directed to resume the usual schedule by taking the next dose at the regular time. The guidance specifies that a double dose must not be taken to make up for a forgotten dose.

Q: Are there specific laboratory tests recommended while on Respair?

A: While routine tests are not mandated for all patients, official post-marketing reports note the potential for increased liver enzyme levels and other rare biological changes. These potential changes may necessitate laboratory monitoring if related symptoms occur.

How should Respair be stored and disposed of?

Respair must be stored in its original container at room temperature, away from moisture, heat, and direct light. It is essential to keep the medication in a secure location, out of sight and reach of children and pets, to prevent accidental ingestion or misuse.

Never use Respair past its expiration date or if the tablets show signs of discoloration, crumbling, or other physical changes. Proper disposal is crucial for safety and environmental protection. The preferred method for discarding unused or expired medication is through a drug take-back program or a medication disposal kiosk, often found at pharmacies or law enforcement facilities. If a take-back option is unavailable, the medication should generally be mixed with an unpalatable substance (like dirt or used coffee grounds), placed in a sealed plastic bag, and then disposed of in the household trash. Do not flush this medication down a toilet or pour it down a sink unless the product's accompanying information explicitly instructs you to do so.

Respair